[go: up one dir, main page]

WO2016167577A1 - Composition pour la prévention ou le traitement de maladies inflammatoires ou de la douleur - Google Patents

Composition pour la prévention ou le traitement de maladies inflammatoires ou de la douleur Download PDF

Info

Publication number
WO2016167577A1
WO2016167577A1 PCT/KR2016/003903 KR2016003903W WO2016167577A1 WO 2016167577 A1 WO2016167577 A1 WO 2016167577A1 KR 2016003903 W KR2016003903 W KR 2016003903W WO 2016167577 A1 WO2016167577 A1 WO 2016167577A1
Authority
WO
WIPO (PCT)
Prior art keywords
rhizoma
extract
ginsenoside
radix
preparata
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/003903
Other languages
English (en)
Inventor
Jang Woo Shin
Myung Yong Park
Hyun Je Park
Seong Kyu Kim
Sang Ho Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of WO2016167577A1 publication Critical patent/WO2016167577A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A23V2250/2124—Ginseng
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a composition for preventing or treating inflammatory diseases or pain, more specifically it relates to the composition for preventing or treating inflammatory diseases or pain, which comprises a complex extract of Notoginseng Radix Et Rhizoma ( Panax notoginseng ) and Rehmanniae Radix Preparata ( Rehmannia glutinosa ) having the weight ratio of ginsenoside Rg3 to ginsenoside Rb1 of 0.20 or more as an active constituent.
  • Notoginseng Radix Et Rhizoma Panax notoginseng
  • Rehmanniae Radix Preparata Rehmannia glutinosa
  • Non-Steroidal Anti-inflammatory Drugs such as phenylbutazone, diclofenac, aceclofenac, etc. have excellent anti-inflammatory analgesic effects, it is also known that many side effects are occurred in a long-term use.
  • diseases relating to arthritis are representative degenerative, intractable diseases that about 12% of the populations of the whole world suffer and there are about 2 million of patients in South Korea.
  • Arthritis is a disease name generally called as those systemic symptoms are occurred in muscular skeletal system due to the inflammatory change in the musculoskeletal and connective tissues.
  • the said diseases are characterized by the chronic inflammation often causing permanent tissue damage, malformation, degeneration and disorder by affecting on joint, bone, cartilaginous tissue or spinal cord (Hofbause, L. C., Heufelder, A. E.: The role of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in the pathogenesis and treatment of rheumatoid arthritis, Arthritis and Rheumatism 44:253-259, 2001). Arthritis is classified into degenerative arthritis (osteoarthritis), rheumatoid arthritis, extraarticular rheumatism or collagen disease.
  • the degenerative arthritis is a disease exhibiting the topical degenerative change that the articular cartilage is worn out and disappeared. Although a cause of it is unclear, it has been known that it is closely related to signs of decrepitude or the excessive weight, and degenerative changes of articular cartilage are primarily appeared in this disease.
  • the degenerative changes are started from the articular cartilage, cartilage cells are necrotized, and substrates are destroyed by Cathepsin B, Cathepsin D, Collagenase and the like.
  • As a generation of proteoglycan and collagen can not be kept up the degree of the destruction and adaptability of the cartilage against external force is gradually decreased, and finally there is a point of view such as microfracture, etc in subchondral bone tissue.
  • Rheumatoid arthritis among arthritis is systemic chronic inflammatory diseases which morbid symptoms are symmetrically occurred in diathrosis, and is known as autoimmune diseases which are occurred by abnormality of the immune system and the cause of which has not been clearly identified yet.
  • the diseases are characterized by continuous inflammatory synovitis causing the cartilage destruction and bone erosion, which leads to the structural abnormality of articular.
  • Symptoms relating to the rheumatoid arthritis include arthredema, joint tenderness, inflammation, morning stiffness and in particular pain when bending joints.
  • the structural damages including articular destruction together with bone erosion are occurred in a subject developing the arthritis (Firestein, G.S.: Evolving concept of rheumatoid arthritis, Nature 423:356-361, 2003).
  • the patient may have other clinical symptoms such as damages of various organs including damages of skin, kidney, heart, lung, central nervous system and eye due to angiitis relating to an autoimmune process.
  • the treatment methods of degenerative arthritis and rheumatoid arthritis being used at present are as follows.
  • the drug which is used a lot in the early treatment stage is non-steroidal anti-inflammatory drugs (NSAIDs), and such NSAIDs can improve the symptoms a little but can not prevent the cartilage loss in parts of articulation or the progress of disease.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • about a half of patients using such treatment should discontinue the treatment within 1 year since side effects in gastroenteric system, central nervous system, blood-forming organ, kidney, liver, etc. are occurred when taken for a long period(Langenegger, T., Michel, B. A. : Drug treatment for rheumatoid arthritis., Clin Orthop. 366:22-30,1999).
  • compound drugs comprising gold (gold drugs; gold sodium thiomalate, gold sodium thiosulfate) or antiarthritis agent (disease modifying anti-rheumatic drugs, DMARDs) such as penicillamine, anti-malarials, and the like are used.
  • gold drugs gold sodium thiomalate, gold sodium thiosulfate
  • antiarthritis agent disease modifying anti-rheumatic drugs, DMARDs
  • a periodontal disease refers to a disease occurred in periodontium consisting of alveolar bone, gingiva, periodontal ligament and cement, and is classified into gingivitis, localized in gum, and periodontitis that periodontal ligament and alveolar bone are destructed by deepening of gingivitis.
  • the causes of the periodontal disease are various, but the representative cause is due to bacteria.
  • the periodontium is directly destructed by the cellular toxins such as hydrogen sulfate, ammonia and toxic amine which are a metabolite of anaerobic gram-negative bacteria, or the destruction of periodontium and inflammation are caused by various cytokines such as active oxygen, prostaglandin, leukotriene, histamine, interleukin, etc., which are secreted by the action of immune system activated by lipopolysacchride (LPS), the constitutive component of the cell wall of anaerobic gram-negative bacteria.
  • LPS lipopolysacchride
  • a gingival retraction is occurred by the depomposition of collagen, the substrate of periodontium by enzyme such as collagenase from bacteria and leukocyte, and if it is neglected continuously, the periodontal disease is deteriorated. Therefore, an anti-bacterial action, cytostatic action and removal of the toxic products against anaerobic gram-negative bacteria, which is the basic pathogenetic cause of periodontal disease, and recovery of the lossed periodontium, etc. are important factors for preventing or treating periodontal disease.
  • surgical care scaling, root planning, gingival curettage, periodontal regeneration
  • non-surgical care medium therapy
  • the surgical care which can be the most effective method, has a problem that the treatment for periodontal disease is not effectively made and mostly proceeded into the chronic disease due to the discomfort that the patient should visit the dentist for the treatment and the limitation that the patient should visit the dentist after proceeding the disease rather than the prevention of disease.
  • antibiotics which are used in the additional treatment, have the side effects due to the excessive transfer of drugs even to unnecessary parts and also the problem being reported the case that bacteria of periodontal disease exhibiting a resistance are isolated recently.
  • compositions for preventing or treating an inflammatory disease for example, osteoarthritis, rheumatoid arthritis, periodontitis
  • pain which can minimize the side effects of conventional inflammatory analsegic drugs, the arthritis treating agent and the periodontal disease treating agent.
  • composition having the certain ratio between ginsenoside Rb1 and ginsenoside Rg3, by the heat treatment, etc. of the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata has an excellent anti-inflammatory activity, as well as the effect of inhibiting pain in arthritis, protecting cartilage, inhibiting the expression of inflammatory cytokine and treating periodontal disease, and then completed the present invention.
  • the object of the present invention is to provide the composition for preveneting or treating inflammatory disease or pain.
  • Another object of the present invention is to provide a health functional food for preventing or improving the inflammatory disease or pain.
  • the present invention provides a composition for preventing or treating inflammatory diseases or pain, which comprises, a complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata wherein a weight ratio of ginsenoside Rg3 to ginsenoside Rb1 is 0.20 or more, as an active constituent.
  • Notoginseng Radix Et Rhizoma means a root and/or Rhizoma of Panax Notoginseng .
  • Panax Notoginseng is a perennial herb of Araliaceae, and is smaller than ginseng, has seven (7) leaflets, form of small spindle shape, and is cultivated at Unnam, Sacheon, etc. of South of China. Its root has 3 to 8% of saponin, and its main component is ginsenosides Rb1, Rg1, Rd, and notoginsenosides R1, R2, Fa, Fc, and comprises small amount of ginsenosides F1, F2, Ra1, Ra2, Rb2, Rb3, Re, Rc, Rf, etc.
  • the essential oil component is lower than ginseng and comprises oleanolic acid, etc.
  • the root has haemostatic action and cardiotonic action, and has been found as having the efficacy that increases blood flow amount of coronary artery, reduces oxygen consumption amount in heart and reduces contents of lipid and cholesterol in blood.
  • Rehmanniae Radix Preparata is one dried after steaming roots of medicinal plant belonging to Scrophulariaceae, is used as medicine in oriental medicine clinic, and the original one is referred to as the raw Rehmannia glutinosa , the dried one is referred to as the dried Rehmannia glutinosa , and the one which is made by soaking Rehmanniae glutinosa into alcohol and then steaming and drying it in nine times repeatedly is referred to as Rehmanniae Radix Preparata and considered as having the greatest medicinal effect.
  • the weight ratio of ginsenoside Rg3 to ginsenoside Rb1 may be 0.20 to 30, and preferably 0.20 to 25. More preferably, it is 0.20 to 21.
  • the said complex extract can further comprise ginsenosides Rd, Rh1, Rh4, Rk1, Rk3 and Rg5, in addition to gensenoside Rb1 and Rg3.
  • the weight ratio of the total amounts of said ginsenosides Rh1, Rh4, Rk3, Rg5, Rk1 and Rd to ginsenoside Rb1 may be 1.1 to 75.
  • 7.0 % or more by weight of ginsenoside Rg3 compared to the total contents of the said ginsenosides Rb1, Rg3, Rd, Rh1, Rh4, Rk1, Rk3 and Rg5 can be comprised. Further, said ginsenoside Rg3 can be comprised in 7.0 to 25.0 % by weight, and in 9.0 to 23.0 % by weight.
  • the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata can be one extracted from Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata, or a mixture of single extract of Notoginseng Radix Et Rhizoma and single extract of Rehmanniae Radix Preparata. Further, it is preferable that the said complex extract is the extract of the mixture of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata, but it is not limited to such extract.
  • the complex extract of the present invention can be extracted from the botanical raw material itself as its original form or as a finely cutting or powdery form by the conventional extraction method such as, maceration, digestion, heating, and etc.
  • the conventional extraction method such as, maceration, digestion, heating, and etc.
  • Notoginseng Radix Et Rhizoma is used by powdering
  • Rehmanniae Radix Preparata is used by itself or by finely cutting.
  • the extraction solvent can be water, alcohol or a mixture thereof, and it is preferable to use the mixed solvent of water/alcohol.
  • the said mixed solvent of water/alcohol may be aqueous alcohol solution of 30 to 95 % by volume (v/v), preferably aqueous alcohol solution of 50 to 70 % by volume (v/v), more preferably aqueous alcohol solution of 50 % by volume (v/v).
  • the said alcohol may be methanol, ethanol or isopropanol, preferably methanol or ethanol, more preferably ethanol.
  • Notoginseng Radix Et Rhizoma, Rehmanniae Radix Preparata or their mixture are extracted in water/alcohol-mixed solvent, preferably water/methanol-mixed solvent or water/ethanol-mixed solvent, more preferably water/ethanol-mixed solvent at the temperature of 70 ⁇ 85 °C for 2 ⁇ 4 hours to obtain the extract.
  • water/alcohol-mixed solvent preferably water/methanol-mixed solvent or water/ethanol-mixed solvent, more preferably water/ethanol-mixed solvent at the temperature of 70 ⁇ 85 °C for 2 ⁇ 4 hours
  • the above procedure can be repeatedly performed several times, and the said extract can be concentrated under reduced pressure in vacuum codition, at the temperature of 60°C or less.
  • the concentrate can be treated by heat, acid, enzyme, or ultrasonic treatment, etc. to obtain the composition wherein the weight ratio of ginsenoside Rg3 to ginsenoside Rb1 is 0.20 or more.
  • the complex extract of the present invention may be one extracted from Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata mixture.
  • the weight ratio of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata comprised in the said mixture may be 3:1 to 18:1.
  • the said weight ratio may be 4:1 to 16:1, more preferably may be 8:1 to 16:1, most preferably may be 8:1.
  • the complex extract may be the mixture of single Notoginseng Radix Et Rhizoma extract and single Rehmanniae Radix Preparata extract.
  • the mixed solvent of water/alcohol preferably the mixed solvent of water/methanol or the mixed solvent of water/ethanol, more preferably the mixed solvent of water/ethanol
  • the single Notoginseng Radix Et Rhizoma extract or single Rehmanniae Radix Preparata extract can be prepared by treating a heat, acid, enzyme, or ultrasonic, etc. after the concentration.
  • the weight ratio of ginsenoside Rg3 to ginsenoside Rb1 can be 0.20 or more in the mixture of the single Notoginseng Radix Et Rhizoma extract and single Rehmanniae Radix Preparata extract, the process of heat treatment, acid treatment, enzyme treatment, ultraviolet treatment, etc. can be omitted in the preparation of the single Notoginseng Radix Et Rhizoma extract or single Rehmanniae Radix Preparata extract.
  • the weight ratio of the mixture of the single Notoginseng Radix Et Rhizoma extract and single Rehmanniae Radix Preparata extract may be 1.5 to 9:1, preferably 3 to 6:1, more preferably 3:1.
  • yields of the single Notoginseng Radix Et Rhizoma extract and single Rehmanniae Radix Preparata extract may be different to each other by the extraction method. Therefore, regulating the mixing ratio of the original botanical raw materials by considering the yield, the weight of the mixture of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata may be 3:1 to 18:1, preferably 4:1 to 16:1, more preferably 8:1 to 16:1, and the most preferably 8:1 like the extract of the mixture of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata.
  • Notoginseng Radix Et Rhizoma was used as a powdered. If it is not powdered, the extraction efficiency of the active constituent may be lowered.
  • Each of Notoginseng Radix Et Rhizoma powder and Rehmanniae Radix Preparata, or the mixture of them was prepared, extracted with reflux by water or the mixed solvent of water/alcohol in 5 to 10 folds of the total botanical raw materials as the extraction solvent at the temperature of 75 ⁇ 85 °C for 4 ⁇ 6 hrs and filtered. Water or water/alcohol-mixed solvent in 5 to 10 folds of the total weight of the botanical raw material was added to each of the residue, warmed at the temperature of 75 ⁇ 85 °C to re-extraction and then filtered.
  • the extract obtained by extracting with water or water/alcohol-mixed solvent over the first and second steps are filtered and concentrated, and then some of ginsenoside Rb1 were converted into ginsenoside Rg3 by heat-treatment at 90 °C or more to obtain the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata where the weight ratio of ginsenoside Rg3 to ginsenoside Rb1 is 0.20 or more.
  • the extract obtained by such process can be additionally concentrated to obtain wet extract, and the obtained extract can be lyophilized (freeze-dried) to obtain extract in the powder state, and excipients are added and spray-dried to obtain extract in the powder state.
  • inflammatory diseases in the present invention can be arthritis or periodontal disease.
  • arthritis in the present invention can be degenerative arthritis (osteoarthritis) or rheumatoid arthritis.
  • gingivitis gingivitis or periodontitis.
  • room temperature in the present invention means 15 to 25 °C.
  • prevention in the present invention means all behaviors inhibiting or delaying inflammatory diseases or pain by administering the composition of the present invention.
  • composition of the present invention can further comprise the known natural products or extracts thereof, or active functional substances, etc., in addition to the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata wherein the weight ratio of ginsenoside Rg3 to ginsenoside Rb1 is 0.20 or more.
  • Such components can be used alone or in combination.
  • the complex can additionally comprises one or more kinds of the pharmaceutically acceptable carriers, in addition to the active constituent mentioned above.
  • the pharmaceutically acceptable carrier can be saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrine solution, glycerol, ethanol and mixtures of one or more of these components, and if necessary, other customary additives such as an anti-oxidant agent, buffering agent, bacteristatic agent can be added.
  • an injectable formulation such as an aqueous solution, suspension and emulsion, a pill, a capsule, a granule or tablet by additionally adding a diluent, dispersing agent, surfactant, binding agent and lubricant.
  • a diluent such as an aqueous solution, suspension and emulsion, a pill, a capsule, a granule or tablet
  • it can be preferably formulated by the proper method according to the respective diseases or the components by using the method disclosed in Remington's Pharmaceutical Science (a recent edition), Mack Publishing Company, Easton PA.
  • composition of the present invention can be administered parenterally (for example, by intravenous, subcutaneous, peritoneous or topical administration) or orally, and the range of the dosage may be various according to the weight, age, sex, health state of the patient, diet, administration time, administration mode, excretion rate, and severity of the disease, etc.
  • composition of the present invention can be administered by an oral administration, intraperitoneal administration, intraveneous administration, intramuscular administration, subcutaneous administration, intraendotheial administration, intranasal administration, intrapulmonary administration, endorectal administration, intracavitary administration, intrathecal administration, and is not limited thereto.
  • the daily dosage is 0.1 to 1000.0 mg/kg based on the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata, preferably 0.1 to 500.0 mg/kg, and it is more preferably administered in one time or by dividing several times per day.
  • the present invention can be provided in the form of oral composition for effectively preventing or treating inflammatory diseases or pain, and the formulation of the oral composition is not particulary limited and can have conventional formulation. Specifically, it can have the formulation such as toothpaste, mouth washes or mouth refreshener, etc.
  • the oral composition provided by the present invention can comprise the various bases and additives necessary for formulating depending on the formulation, and the kinds and amounts of such components can be selected by a person skilled in the art.
  • the formulation of the oral composition is tooth paste, it can be prepared by adding an abrasive, wetting agent, foaming agent, binding agent, sweetening agent, pH regulator, preservative, active ingredient, perfume, whitening agent, colorant, resolvent, etc.
  • the known natural product or extract thereof that effective to inflammatory disease or pain may be an Trichosanthes kirilowii Maxim extract, Aralia cordata extract, Magnolia officinalis extract, Acyranthes bidentata extract, Kalopanax Pictus extract, Citrus reticulata extract, Cnidium japonicum extract, Foeniculum vulgare extract, Liriope platyphylla extract, Smilax china extract, Clematis mandshurica extract, Gynostemma pentaphyllum extract or Actnidia Polygammae extract, etc.
  • the ratio of the known natural product, extract thereof and active functional material which are known to be effective for the above inflammatory diseases or pain is not so important, it is general to be selected in the range of 1 to about 90 parts by weight per 100 parts by weight.
  • the present invention provides the health functional food for preventing or improving inflammatory diseases or pain, which comprises, the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata wherein weight ratio of ginsenoside Rg3 to ginsenoside Rb1 is 0.20 or more as an active constituent.
  • improvement means all behaviors which improves or advantageously changes inflammatory diseases or pain by administering the composition according to the present invention.
  • the health functional food of the present invention includes the foods defined in the FUNCTIONAL HEALTH FOODS ACT of Korea, established on August 26, 2002.
  • the health functional food includes foods which are prepared and processed in the form of a tablet, capsule, powder, granule, liquid, pill, etc., by using raw materials or ingredients having the functionality useful for human body.
  • the health functional food for preventing or improving the said inflammatory diseases or pain can additionally comprise sitologically acceptable additives.
  • the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata wherein the weight ratio of ginsenoside Rg3 to ginsenoside Rb1 is 0.20 or more according to the present invention can be added to the health functional food for improving inflammatory diseases or pain, and if the extract according to the present invention is used as the food additive, the mixed botanical raw material extract can be used by itself or together with other foods or food components, and can be properly used according to the conventional method.
  • the mixed amount of the active constituents can be determined according to the object to be used (prevention, health or therapeutic treatment).
  • the extract of the present invention is added in the amounts of 100 wt% or less, preferably 50 wt% or less to the raw materials in preparing foods or beverages.
  • the amount can be less than the above range, and since there is no problem in light of safety, the active constituents can be used in the amounts of the above range or more.
  • the examples of the food to which the above materials can be added include meat, sausage, bread, chocolate, candy, snack, cracker, pizza, ramen, other noodles, gum, diary products including ice creams, various soups, beverage, tea, health drink, alcohol beverage and vitamin complex, etc. and include all health foods in the common sense.
  • the health beverage composition of the present invention can comprise various flavoring agent or natural carbohydrate, etc., as an additional component like the conventional beverage.
  • the said natural carbohydrate is monosaccharide such as glucose, fructose, disaccharide such as maltose, sucrose, polysaccharide such as dextrine, cyclodextrine, sugar alcohol such as xylitol, sorbitol, erythritol, etc.
  • the sweetening agent such as taumatin, stevia extract, or the synthetic sweetening agent such as saccharin, aspartame, etc. can be used.
  • the ratio of the natural carbohydrate is generally about 0.1 ⁇ 20.0 g, preferably about 1 ⁇ 10.0 g per 100 ml of the composition of the present invention.
  • the health functional food composition of the present invention can comprise various nutrients, vitamin, electrolyte, flavoring agent, colorant, pectic acid and salts thereof, alginic acid and salts thereof, organic acid, protective colloidal thickening agent, pH regulator, stabilizer, preservative agent, glycerin, alcohol, carbonization agent, etc., in addition to the above components.
  • the composition of the present invention can comprise flesh for preparing the natural fruit juice, fruit juice beverage and vegetable beverage.
  • Such components can be used alone or in combination. Although the ratio of such additives is not important, it is general that they are selected in the range of 0.05 ⁇ 50 parts by weight per 100 parts by weight of the composition of the present invention.
  • the present invention provides the method for preventing or treating inflammatory diseases or pain by administering the composition for preventing or treating inflammatory diseases or pain, which comprises the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata wherein the weight ratio of ginsenoside Rg3 to ginsenoside Rb1 is 0.20 or more, as the active constituent, to the subject in need thereof including mammal.
  • the present invention provides the use of the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata wherein the weight ratio of ginsenoside Rg3 to ginsenoside Rb1 is 0.20 or more for preparing the pharmaceutical preparation for preventing or treating inflammatory diseases or pain.
  • composition according to the present invention has very excellent anti-inflammatory and analgesic effects, as well as the excellent treatment effects for arthritis or periodontal disease, it can be used in the pharmaceutical composition or health functional food for preventing, treating or improving inflammatory diseases or pain.
  • Figs. 1a and 1b represent the chemical fingerprint results of the high performance liquid chromatogram exhibiting each complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of preparation example 1-1, and Comparative preparation example 1.
  • Fig. 2 is a histopathological photograph of knee joint and represents the effects that the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of the present invention affects the inhibition of cartilage destruction.
  • A represents a normal control (NC group)
  • B represents MIA group
  • C represents Celecoxib group
  • D represents preparation example 1-1 group
  • E represents comparative preparation example 1 group, respectively.
  • Fig. 3 is a figure exhibiting the influences of the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of the present invention on arthritis index of type 2 collagen-induced arthritis model.
  • 1 represents the normal group
  • 2 represents the control group
  • 3 represents preparation example 1-1 150 mg/kg group
  • 4 represents preparation example 1-1 300 mg/kg group
  • 5 represents celecoxib 100 mg/kg group, respectively.
  • Fig. 4 is a figure exhibiting the influences of the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of the present invention on the improvement of clinical attachment level (CAL) in the ligature-induced periodontal disease model.
  • 1 represents the normal control group
  • 2 represents the negative control group
  • 3 represents preparation example 1-1 7.5 mg/kg administration group
  • 4 represents preparation example 1-1 30 mg/kg administration group
  • 5 represents preparation example 1-1 90 mg/kg administration group, respectively.
  • Fig. 5 is a figure exhibiting the influence of the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of the present invention on the inhibition of thermal pain.
  • 1 represents the control group
  • 2 represents preparation example 1-1 25 mg/kg group
  • 3 represents preparation example 1-1 100 mg/kg group
  • 4 represents preparation example 1-1 300 mg/kg group
  • 5 represents celecoxib 50 mg/kg group, respectively.
  • Fig. 6 is a figure representing results of the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of the present invention on Tail-flick test.
  • 1 represents control group
  • 2 represents preparation example 1-1 50 mg/kg group
  • 3 represents preparation example 1-1 200 mg/kg group
  • 4 represents preparation example 1-1 600 mg/kg group
  • 5 represents celecoxib 100 mg/kg group, respectively.
  • Fig. 7 is a figure representing the result of the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of the present invention on acetic acid- writhing test.
  • 1 represents control group
  • 2 represents preparation example 1-1 50 mg/kg group
  • 3 represents preparation example 1-1 200 mg/kg group
  • 4 represents preparation example 1-1 600 mg/kg group
  • 5 represents celecoxib 100 mg/kg group, respectively.
  • Fig. 8 is a figure representing the result of the complex Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of the present invention on rotarod test.
  • 1 represents rat control
  • 2 represents preparation example 1-1 100 mg/kg group
  • 3 represents preparation example 1-1 300 mg/kg group
  • 4 represents mouse control group
  • 5 represents preparation example 1-1 300 mg/kg group
  • 6 represents preparation example 1-1 600mg/kg group, respectively.
  • Preparation Example 1 The preparation of the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata (the extract of the mixture of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata)
  • Notoginseng Radix Et Rhizoma was obtained from China and purchased from Myohyang Ibc. and Pharmaline Inc. Rehmanniae Radix Preparata was used after purchasing the distributed products in Korea via Puremind. After identifying the presence or absence of foreign matters on each of the botanical raw materials of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata, only botanical raw materials in the clear state were selected and used in the Experiments. Notoginseng Radix Et Rhizoma was used after finely grinding. That is, the powder of Notoginseng Radix Et Rhizoma was used. Rehmanniae Radix Preparata was used as the original form itself.
  • Preparation example 1-2 was prepared by the same method of the above preparation 1-1, except for refluxing at 100 °C for 8 hrs instead of 16 hrs in the preparation example 1-1.
  • Preparation example 1-3 was prepared by the same method of the above preparation 1-1, except for refluxing at 100 °C for 32 hrs instead of 16 hrs in the preparation example 1-1.
  • Preparation example 1-4 was prepared by the same method of the above preparation 1-1, except for refluxing at 100 °C for 64 hrs instead of 16 hrs in the preparation example 1-1.
  • Preparation example 1-5 was prepared by the same method of the above preparation 1-1, except for the weight ratio of Notoginseng Radix Et Rhizoma powder to Rehmanniae Radix Preparata of 16:1 instead of 8:1 in the preparation example 1-1.
  • Preparation example 1-6 was prepared by the same method of the above preparation 1-1, except for the weight ratio of Notoginseng Radix Et Rhizoma powder to Rehmanniae Radix Preparata of 4:1 instead of 8:1 in the preparation example 1-1.
  • Notoginseng Radix Et Rhizoma was used by finely grinding. 200 g of Notoginseng Radix Et Rhizoma was placed in 3 L flask, was extracted by 1.4 L of 50%(v/v) ethanol at 84 °C with stirring under reflux for 4 hrs, and filtered and then the residue was extracted by stirring under reflux by 1.0 L of 50 %(v/v) ethanol at 84 °C for 2 hrs. After gathering the resulting extract and filtering it, it was concentrated under reduced pressure in vacuum condition to be about 20 brix and then was refluxed at 100 °C for 16 hrs.
  • Rehmanniae Radix Preparata was used as original form itself. 200 g of Rehmanniae Radix Preparata was placed in 3 L flask, was extracted by 1.4 L of 50%(v/v) ethanol at 84 °C with stirring under reflux for 4 hrs and filtered and then the residue was extracted with stirring under reflux by 1.0 L of 50 %(v/v) ethanol at 84 °C for 2 hrs. After gathering the said extract and filtering it, it was concentrated under the vacuum-decompression by rotary vacuum condensing evaporator (N-12, EYELA) at 60 °C or less, powdered by lyophilization (freeze-drying) to use it in the Experiment. The yield was 67%.
  • rotary vacuum condensing evaporator N-12, EYELA
  • the complex extract of single Notoginseng Radix Et Rhizoma extract and single Rehmanniae Radix Preparata extract was prepared by mixing the weight ratio of 6:1 of single Notoginseng Radix Et Rhizoma extract to single Rehmanniae Radix Preparata extract, as prepared in the above.
  • the complex extract of the single Notoginseng Radix Et Rhizoma extract and single Rehmanniae Radix Preparata extract was prepared by mixing the weight ratio of 3:1 of the single Notoginseng Radix Et Rhizoma extract to the single Rehmanniae Radix Preparata extract, as described in the above preparation example 2-1.
  • Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata After identifying the presence or absence for foreign matters for each Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata, only the botanical raw material with the clear state was selected and used in the experiment. Notoginseng Radix Et Rhizoma was used by finely grinding. Rehmanniae Radix Preparata was used as the original form itself.
  • Comparative Preparation example 2 was prepared by the same method of the above preparation example 1-1, except for refluxing at 100 °C for 2 hrs instead of 16 hrs in the preparation example 1-1.
  • Comparative Preparation example 3 was prepared by the same method of the above preparation example 1-1, except for refluxing at 100 °C for 4 hrs instead of 16 hrs in the preparation example 1-1.
  • Each of the complex-extracts of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of preparation examples 1 to 2 and Comparative preparation examples 1 to 3 was used as a sample.
  • 500 mg of sample was precisely weighed, was placed in 50 mL volume of flask with 25 mL of water, shaked by ultrasonic for 1 hr with swaying from time to time and then 20 mL of methanol was added and shaked by ultrasonic for 30 minutes. After allowing this liquid to be at a room temperature, it was adjusted into the marked line with methanol and was used as a test solution after filtering it with 0.45 ⁇ m membrane filter.
  • ginsenoside Rb1 reference standard preparation was precisely weighted, and was concisely adjusted into 50 mL by melting it in methanol. 5 mL of this liquid was placed in a flask with 10 mL volume, was adjusted into the marked line with water, filtered with 0.45 ⁇ m membrane filter and then was used as the standard solution. 20 ⁇ L of each the test solution and standard solution was tested according to the liquid chromatographic method under the following condition and then the peak areas for the test solution and standard solution were determined.
  • the reference standard product for analytical marker component was purchased from Sigma-Aldrich, chromadex, Embolaboratory.
  • Zorbax SB C18(3.5 ⁇ m, 4.6 ⁇ 150 mm) column was used and the mixed solvent of water and acetonitrile was used as the mobile phase.
  • the ratio of the organic solvent was gradually increased to be from 1 % to 80 % of ratio of acetonitrile at 40 minute.
  • the determination wavelength is 203 nm.
  • ginsenoside Rg3 (G.Rg3) was generated, and in addition to that, ginsenoside Rh1 (G.Rh1), ginsenoside Rh4 (G.Rh4), ginsenoside Rk3 (G.Rk3), ginsenoside Rg5 (G.Rg5), ginsenoside Rk1 (G.Rk1), ginsenoside Rg2 (G.Rg2), etc. were also generated.
  • the acute toxicity test was performed with the specific pathogen-free (SPF) 6-week old rats as the test animals.
  • the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of Preparation Example 1-1 of the present invention was dissolved in 0.5 % carboxymethyl cellulose (CMC) and then orally administered once to the rats (ten rats / group) fasted for 17 hrs in a volume of 5 g/kg. After the administration of the test material, a fate of animals, the clinical symptoms and the weight change were observed, and abnormality for the abdominal organs and thoracic organs was observed with the naked eye after a necropsy.
  • CMC carboxymethyl cellulose
  • the mixed botanical raw materials extract of the present invention did not exhibit up to 5 g/kg in rats and had 5 g/kg of the minimal lethal dose (LD 50 ) in the oral administration, and thus, it was determined as being safe.
  • the botanical raw materials used in the present invention are classified into food materials, it is considered that there is no problem in the safety of the complex botanical raw material extract, but the inventors of the present invention performed the repetition toxicity test, using the following method, to confirm the safety of the complex botanical raw material extract for oral administration.
  • the chronic toxicity test was performed with the specific pathogen free (SPF) 6-week old rats as the test animals.
  • the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of Preparation Example 1-1 of the present invention was dissolved in 0.5 % CMC and then orally administered to the rats (ten rats / group) in a maximal concentration of 2400 mg/kg and middle volume of 1200 g/kg and low volume of 600 mg/kg in a geometric ratio of 0.5 for 26 weeks.
  • rats ten rats / group
  • a fate of animals, the clinical symptoms, the intake of an edible water and food, the eye examination and the weight change were observed, and abnormality for the abdominal organs and thoracic organs was observed with the naked eye after a necropsy.
  • organ weight, hematological assay, blood biochemical assay, histopathological assay, urine analysis, and etc. are gathered, and safety was evaluated
  • the repetitive toxicity test was performed to estimate the toxic response and its safety exhibited for male and female, 6-weeks Sprague-Dowley rat orally administered by the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of Preparation Example 1-1 of the present invention for 26 weeks. Also, having 4 weeks recovery period to confirm whether the reversibility for the toxic change was present. 2,400 mg/kg of the test material was set as high volume, and the middle volume (1,200 mg/kg) and low volume (600 mg/kg) were set in 0.5 of the geometric ratio. Twelve animals per group were set, and the recovery group was set by adding six animals to the high volume group and control group.
  • Example 1 Identification of NO inhibitory effect, an index relating to the inflammation
  • the important index (factor) in the inflammation, of the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata 2 x 10 5 cells of mouse macrophage cell line RAW 264.7 were plated into 24 well plate, were treated with 100 ⁇ g/mL of complex extracts of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of Preparation Examples 1 to 2 and Comparative Preparation Examples 1 to 3 on the next day, and 1hr later, cells were activated to generate NO by adding lipopolysaccharide (LPS) to be 2 ⁇ g/mL.
  • LPS lipopolysaccharide
  • Nitrite (NO) standard product included in Griess reagent system kit(Promega,USA) was prepared into 100 ⁇ M with DMEM. After incubating 24hrs, medium collected from each well of 24 well plates and the standard liquid for calibration curve were added to each well of 96 well plates for 50 ⁇ L. 100 ⁇ M of Nitrite(NO) standard liquid was diluted into 1/2 with DMEM, respectively to prepare the standard liquid for calibration curve as 50, 25, 12.5, 6.25, 3.13 and 1.56 ⁇ M. 0 ⁇ M of the standard liquid for calibration curve used DMEM. 50 ⁇ L of Sulfanilamide solution in Griess reagent system kit was added to each well of 96 well plates, and then left at the room temperature for 10 minutes while blocking light.
  • MIA Monosodium iodoacetate
  • Naive Normal Control group
  • the test materials (Preparation Example 1-1, Comparative Preparation Example 1, respectively) were dissolved in 0.5 % CMC solution and used after homogenizing to the max with sonicator.
  • the Test material and Control material (Celecoxib, 20 mg/kg) were orally administered once per day for total 21 days from 7 days (day 7) after MIA injection to 28 day (day 27).
  • Normal Control (NC) and Osteoarthritis-Induced Aminals (MIA) were orally administered with 0.5% CMC solvent agent in the volume of 10 mL/kg once everyday for the same period as the test material.
  • the numbers of animals were 10 per each, and each test and control materials were administered at the constant time everyday.
  • the test drug was administered in the volume of 25 mg/kg.
  • the threshold of thermal pain was determined using thermal pain determination device (IITC life science, USA).
  • the plantar of the right rear paw was adapted at 30 °C for 10 minutes , and then the rat was placed on a foothold raised to 50 °C, and the time the licking the rear paw or lifting the paw from the bottom (paw withdrawal latency, PWL) was measured.
  • the determination time for the response was limited to 30 seconds to prevent the damage of the tissue, and the mean value for the determination values for three times determination was used.
  • the determinations were made at the constant time before administration of the drug for degenerative arthritis (day 7) and once a week after the administration (day 14, day 21, day 27) in normal control group, MIA-induced group and test group (Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88, 1988).
  • the variation of PWL at the respective time after administering the drug was calculated in relation to PWL before administering the drug, and student t-test was performed to make the statistical treatment (significance level p ⁇ 0.05, 0.01).
  • the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of Preparation Example 1-1 was the most excellent one in the analgesic effect and was significant in compared to MIA group. In addition, when comparing with the group administered by Celecoxib, it exhibited the statistically significant analgesic effect.
  • the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of Preparation Example 1-1 exhibited the effect greater than the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of Comparative Preparation Example 1.
  • the rat was fasted for 16 hrs before autopsy, laparotomized under anesthesia with diethyl ether and collected the blood from ventral aorta.
  • the gathered blood was left at the room temperature for 30 minutes, put in the Centrifugation Tube (SST tube) which was not treated with heparin, centrifuged with 3000 rpm at 4 °C for 20 minutes to isolate serum and then stored at -70 °C before using in the experiment.
  • SST tube Centrifugation Tube
  • TNF tumor necrosis factor
  • IL-10 interleukin(IL)-1 ⁇
  • IL-10 cytokine relating to the inflammation in the serum
  • the animal was conducted autopsy at the end day of the experiment and the knee joint was taken.
  • the right hip joint and an ankle joint were isolated and extracted not to damage the part of knee joint and then trimming for the soft tissue around the proximal tibia and distal femur knee joint was performed with sterilized surgical knife.
  • the obtained knee joint was immobilized with 10 % formalin for 24 hrs, decalcification was performed while changing the solution with 10 % formic acid at intervals of 24 hrs for 72 hrs before the procedure of the tissue treatment.
  • Sagittal section of knee joint was made via coronal section so that the medial condyle articular surface of the hip joint and tibia was well identified.
  • tissue-processing procedure of general dehydration, transparency and penetration was performed with tissue processor (VIP-5Jr, Sakura Finetek, Japan), the paraffin embedding process was performed and then 5 ⁇ m of thickness of the thin section of the knee joint was prepared with Rotary Microtome (RM2245, Leica 2040, DE). Hematoxylin & Eosin staining and Safranin O staining were performed for each of slices as made. H&E stain: the thin section of the knee joint was performed with deparaffin and moisturization, stained with hematoxylin and eosin, and then dehydrated and clarificated to embed.
  • the tissue slide was observed for the presence or absence of infiltration of the inflammatory cells, destruction level of cartilage and bone, and the histopathological change of articular cartilage.
  • Safranin-O fast green (SOFG) stain The thin section of the knee joint was performed with deparaffinization and moisturization, and then was reacted in Weigert's iron hematoxylin (HT110232, Sigma, St Louis, USA) solution for 10 minutes, washed, and stained with 0.02 % fastgreen (FCF) solution (F7258, Sigma, St Louis, USA) for 5 minutes. After reacting it in 1 % acetic acid solution, it was stained with 0.1 % Safranin O (S2255, Sigma, St Louis, USA) solution.
  • FCF fastgreen
  • the slide stained with Safranin O-fastgreen was washed for 5 minutes so that a nucleus was clear color, and embedded after dehydration and clarification. It was identified as to whether the cartilage tissue was damaged, by using an optical microscope (Olympus BX51, Olympus Optical Co. Japan).
  • osteoarthritis index was obtained by dividing and digitalizing the damage degree thereof, based on the histopathological observation results for the depth and degree of articular cartilage damage, according to the method of Bar-Yehuda, et al. Student t-test was performed and then statistics processing was performed (significance level p ⁇ 0.05, 0.01).
  • an osteoarthritis-induced MIA group had very thin cartilage layer, most of articular cartilages of femur, tibia and kneecap were denatured and necrotized, the form of cartilage cells was disappeared, an erosion was progressed to the radial zone and tidemark, and a granulation tissue carrying an infiltration of the inflammatory cell was found in the surface of the damaged cartilage tissue (See Fig. 2).
  • the subchondral osseous tissue is exposed in joint cavity due to the elimination of cartilage layer, and a reconstruction process was frequently observed due to the fibrous proliferation.
  • the articular cartilage layer of MIA group was mostly destructed, it was very lightly stained or was not stained with Safranine-O staining.
  • Most animals of Comparative Preparation Example 1 group had the thin layer together with the middle level of the damage in the middle zone of the articular cartilage, the destruction of the subchondral osseous tissue and the proliferation degree of the fibrous tissue were observed in the same appearance similar to the lesion in MIA group.
  • the elimination of the denatured articular cartilage layer was observed in some area, and thus, the effect for inhibiting the articular degenerative damage was weakly identified (See Fig. 2).
  • Marginal area and some depth part of articular cartilage were stained with a pale tone.
  • the right knee joint was stained with H & E and Safranin-O fast green and observed.
  • the results of the osteoarthritis index according to the damage level and depth of the articular cartilage in each group and the histopathological opinion based on the above observation was represented in Table 7.
  • the osteoarthritis indexes were identified as 0.0 ⁇ 0.00 and 4.5 ⁇ 0.85 in NC group and MIA group, respectively, and were identified as 3.1 ⁇ 1.52 in Celecoxib group, 2.5 ⁇ 0.85 in Preparation Example 1-1 group and 3.7 ⁇ 1.34 in Comparative Preparation Example 1 group in the test group.
  • mice 5 ⁇ 6 Week-old male DBA1/1J mice were purchased from Central Experimental Animal Co. and the mice were bred under the condition at the temperature of 21 ⁇ 23 °C, humitidy of 40 ⁇ 60 %.
  • Type 2 collagen of bovine (Chondrex, WA, USA) was dissolved in the concentration of 4 mg/mL in 0.1 N acetic acid and then type 2 collagen of bovine was mixed with the same amount of complete Freund's adjuvant (Chondrex, WA, USA). The homogeneous suspension was made with T-connector connected to 3 mL syringe while cooling it with ice.
  • strunt of the mouse was sterilized with alcohol cotton and 100 ⁇ g of collagen was injected into the dermis of strunt part of the mouse. After 2 weeks, 100 ⁇ g of the type 2 collagen of bovine was dissolved, mixed with incomplete Feund's adjuvant (Difco, MI, USA) in the ratio of 1:1 and then administered to the plantar of the mouse.
  • incomplete Feund's adjuvant Difco, MI, USA
  • the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata prepared in Preparation Example 1-1 was dissolved in water to obtain 30 mg/mL and 60 mg/mL, and directly administered to the mouth of the mouse with a 1 mL syringe connected to 1 mL oral gavage once per day from day 4 after the second administration of type 2 collagen of bovine.
  • the examination with the naked eye was performed with the following scores, based on the reference documents.
  • the highest score for the articular lesion was 16 by combining the left and right of fore-paw and rear-paw per a mouse, and the score per a leg was at most 4 (Courtenay JS, Dallman MJ, Dayan AD, et al. : Immunization against heterologous type II collagen induces arthritis in mice. Nature 283: 666-668. 1980).
  • Periodontal disease is the chronic disease due to the complex causes. The most important cause of such periodontal disease can be mentioned as an action of the bacteria. There is a bacterial membrane formed by proteins, foods, etc. in saliva in the surface of teeth, and many bacteria attach to it and be activate. Since most of periodontal patients have defects in the function of defensive cells of the body, they can not resist to various products made by such bacteria, and thus severe destruction of the tissue was occurred.
  • the experimental model of the present experiment was made based on the principle that teeth of beegle dog were tied with silk suture and wire to naturally occur Plaque and Calculus which were the main causes of periodontal disease and to generate inflammation and to finally occur the absorption of alveolar bone.
  • Molar (cheek tooth) of beegle dog was tied with silk wire (6 of teeth per a dog), was fed with liquid feed to induce periodontal disease for 8 weeks, the ligation was lift and then, the tablet comprising 37.5 mg, 150 mg and 450 mg of Preparation Ex. 1-1 was administered to about 10 kg of the dog (three dogs per group) in every one table twice a day to see as to what effect the extract of the present invention affect.
  • CAL Clinical Attachment Level
  • 1 represents the normal control group
  • 2 represents the negative control group
  • 3 represents the administration group of 7.5 mg/kg of Preparation Example 1-1
  • 4 represents the administration group of 30 mg/kg of Preparation Example 1-1
  • 5 represents the administration group of 90 mg/kg of Preparation Example 1-1.
  • CAL of the negative control group was 1.62 mm, but CAL of the group administered by the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of Preparation Example 1-1 exhibited a concentration-dependent reduction, and in the cases of groups administered 30 and 90 mg/kg, they were reduced to 1.17 mm and 1.00 mm, respectively.
  • a mouse was placed on hot pad maintain at 30 °C to be adapted for about 10 minutes.
  • the mouse was placed on hot plate heated and maintained in the constant temperature (55 ⁇ 1 °C) and determined the time that it licked front or hid paws or jumped off (hot plate latency) (Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther. 2005, 312(2):726-732.). In determination, it was performed within 30 seconds (cut-off time: 30 seconds) to prevent the tissue damage, excluding that the mouse took its paw to move.
  • MPE % was 14.3 %, 15.2 % and 18.4 %, respectively and greatly increased compared to the control group of 2.45 %, and the group administered by 300 mg/kg of the complex extract of Notoginseng Radix Et Rhizoma and Rehmanniae Radix Preparata of Preparation Example 1-1 exhibited the result similar to 50 mg/kg of celecoxib.
  • Example 7 Identification of analgesic effect by Acetic acid writhing method (acetic acid-induced writhing test)
  • the analgesic effect was determined according to Koster and Demir Ozkay method (Koster, R., Anderson, M., Beer, E.J., 1959. Acetic acid for analgesic screening. Federation Proceeds 18, 412-416, Demir Ozkay U, Ozkay Y, Can OD. Synthesis and analgesic effects of 2-(2-carboxyphenylsulfanyl)-N-(4-substitutedphenyl)acetamide derivatives. Med Chem Res. 2011; 20:152-157). Various doses of test material or vehicle (0.5% CMC) were administered to the mouse fasted for 12 hrs at 60 minutes before administration.
  • Rotarod test is to estimate the motor coordination of the animal and it was determined by using mouse rotarod system (Panlab, Barcelona, Spain) (Bastos LF1, Prazeres JD, Godin AM, Menezes RR, Soares DG, Ferreira WC, Dutra MM, Machado RR, Coelho MM. Sex-independent suppression of experimental inflammatory pain by minocycline in two mouse strains. Neurosci Lett. 2013 Oct 11; 553: 110-4). The rotary speed of Rotarod was determined by setting 7 rpm for the mouse and 10 rpm for the rat before and after administering the test material.
  • the mouse or rat were placed on the rotating bar before administering the test material, and the time that they come off was identified to determine the baseline value. At this time, the cut-off time was set to 1 minute. After calculating the baseline value, the test material or vehicle (0.5% CMC) was administered to the animal according to the group assignment. The test was performed after lapsing 120 minutes after the administration of the test material.
  • composition of the present invention had the excellent effects for treating and/or preventing inflammatory diseases (for example, arthritis (osteoarthritis, rheumatoid arthritis), periodontitis) or pain.
  • the complex extract of the present invention has the excellent anti-inflammatory and anti pain effects, as well as the very excellent effect for treating arthritis or periodontal disease, it can be used for preventing, treating or improving the inflammatory diseases or pain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pour prévenir, traiter ou améliorer des maladies inflammatoires ou la douleur, la composition comprenant, en tant que constituant actif, un extrait complexe de Notoginseng Radix Et Rhizoma et de Rehmanniae Radix Preparata, un rapport en poids entre ginsénoside RG3 et ginsénoside rb1 étant égal à 0,20 ou plus, ledit extrait présentant non seulement un excellent effet analgésique et anti-inflammatoire, mais aussi d'excellents effets de traitement contre l'arthrite ou les maladies parodontales, et pouvant ainsi être avantageusement utilisé dans la composition pharmaceutique ou des aliments fonctionnels de santé pour prévenir, traiter ou améliorer les maladies inflammatoires ou la douleur.
PCT/KR2016/003903 2015-04-17 2016-04-14 Composition pour la prévention ou le traitement de maladies inflammatoires ou de la douleur Ceased WO2016167577A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0054671 2015-04-17
KR20150054671 2015-04-17

Publications (1)

Publication Number Publication Date
WO2016167577A1 true WO2016167577A1 (fr) 2016-10-20

Family

ID=57127260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003903 Ceased WO2016167577A1 (fr) 2015-04-17 2016-04-14 Composition pour la prévention ou le traitement de maladies inflammatoires ou de la douleur

Country Status (2)

Country Link
KR (1) KR102543158B1 (fr)
WO (1) WO2016167577A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108685931A (zh) * 2018-07-02 2018-10-23 南京类人生物材料有限公司 具有降糖活性的人参皂苷组合物及其应用
CN112255330A (zh) * 2020-09-24 2021-01-22 广东一方制药有限公司 鲜地黄药材、鲜地黄中药配方颗粒的检测方法
JP2025513552A (ja) * 2022-04-25 2025-04-24 ビーティージン カンパニー，リミテッド ジンセノサイド化合物ｋまたは複合ジンセノサイド組成物を含む歯周病の予防または治療用組成物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102205548B1 (ko) * 2020-06-05 2021-01-20 신명섭 안태음 한약재 추출물 함유 치약 조성물
KR102792609B1 (ko) * 2020-12-29 2025-04-08 재단법인 금산인삼약초산업진흥원 항염증 조성물, 이를 포함하는 건강기능식품 및 약학적 조성물
KR102751859B1 (ko) * 2021-09-14 2025-01-10 주식회사 비티진 복합 진세노사이드 조성물을 포함하는 항염증 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040108512A (ko) * 2003-06-17 2004-12-24 주식회사 닥터즈메디코아 혼합 생약재 추출물 및 이를 유효성분으로 함유하는발기부전 치료용 조성물
US20070275103A1 (en) * 2005-01-20 2007-11-29 Jung-Keun Kim Herbal mixture extract of notoginseng radix, rehmanniae radix preparata and acanthopanacis cortex and composition comprising the same for prevention and treatment of arthritis
US20100129476A1 (en) * 2007-04-18 2010-05-27 Oscotec Inc. Composition comprising rehmanniae radix preparata, notoginseng radix or mixture extract thereof for preventing and treating of periodontitis as an effective component
CN101843747B (zh) * 2009-11-25 2011-11-23 北京绿源求证科技发展有限责任公司 一种治疗风湿性关节炎的中药
CN102258722A (zh) * 2011-06-20 2011-11-30 王旭日 一种治疗牙周炎的中药

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130060837A (ko) * 2011-11-30 2013-06-10 가천대학교 산학협력단 가공된 인삼 추출물을 유효성분으로 함유하는 골대사성 질환 치료 및 예방용 약학 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040108512A (ko) * 2003-06-17 2004-12-24 주식회사 닥터즈메디코아 혼합 생약재 추출물 및 이를 유효성분으로 함유하는발기부전 치료용 조성물
US20070275103A1 (en) * 2005-01-20 2007-11-29 Jung-Keun Kim Herbal mixture extract of notoginseng radix, rehmanniae radix preparata and acanthopanacis cortex and composition comprising the same for prevention and treatment of arthritis
US20100129476A1 (en) * 2007-04-18 2010-05-27 Oscotec Inc. Composition comprising rehmanniae radix preparata, notoginseng radix or mixture extract thereof for preventing and treating of periodontitis as an effective component
CN101843747B (zh) * 2009-11-25 2011-11-23 北京绿源求证科技发展有限责任公司 一种治疗风湿性关节炎的中药
CN102258722A (zh) * 2011-06-20 2011-11-30 王旭日 一种治疗牙周炎的中药

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108685931A (zh) * 2018-07-02 2018-10-23 南京类人生物材料有限公司 具有降糖活性的人参皂苷组合物及其应用
CN112255330A (zh) * 2020-09-24 2021-01-22 广东一方制药有限公司 鲜地黄药材、鲜地黄中药配方颗粒的检测方法
CN112255330B (zh) * 2020-09-24 2022-11-08 广东一方制药有限公司 鲜地黄药材、鲜地黄中药配方颗粒的检测方法
JP2025513552A (ja) * 2022-04-25 2025-04-24 ビーティージン カンパニー，リミテッド ジンセノサイド化合物ｋまたは複合ジンセノサイド組成物を含む歯周病の予防または治療用組成物

Also Published As

Publication number Publication date
KR20160124007A (ko) 2016-10-26
KR102543158B1 (ko) 2023-06-14

Similar Documents

Publication Publication Date Title
WO2016167577A1 (fr) Composition pour la prévention ou le traitement de maladies inflammatoires ou de la douleur
KR100540033B1 (ko) 관절염 치료용 생약 조성물 및 그 제조방법
WO2012050396A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du foie
KR101959905B1 (ko) 익지 추출물을 유효성분으로 함유하는 골관절염의 예방, 개선 또는 치료용 조성물
WO2018174589A1 (fr) PROCÉDÉ POUR SOULAGER LA GINGIVITE ET LA PARODONTITE PAR ANTIBIOSE, ANTIOXYDATION, ANTI-INFLAMMATION, SUPPRESSION DE LA PERTE OSSEUSE PARODONTALE ET RÉGÉNÉRATION DE L'OS PARODONTAL AU MOYEN D'UN COMPLEXE D'EXTRAIT DE FEUILLE DE MORINGA OLEIFERA ET D'EXTRAIT D'EUCOMMIA ULMOIDES <i /><i />
KR20110038631A (ko) 연골 재생, 통증 억제 및 부종 억제용 생약조성물
WO2018012848A1 (fr) Composition pharmaceutique permettant de stimuler la croissance des tissus parodontaux et prévenir ou traiter la parodontite, comprenant un mélange d'extrait de cortex de magnoliae officinalis et d'extrait de magnoliae flos en tant que constituant actif
WO2012050398A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du poumon
US20100129476A1 (en) Composition comprising rehmanniae radix preparata, notoginseng radix or mixture extract thereof for preventing and treating of periodontitis as an effective component
WO2012050397A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du rein
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
KR101027555B1 (ko) 혼합 생약 추출물을 유효성분으로 함유하는 간보호 및간염의 예방 및 치료용 조성물
US7794760B2 (en) Herbal mixture extract of Pleurotus eryngii, Acanthopanacis Cortex and Notoginseng Radix and a composition comprising the same for prevention and treatment of periodontitis
WO2017146486A1 (fr) Composition destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate contenant de l'extrait de morus alba linnaeus
WO2018066956A1 (fr) Composition comprenant un extrait composite contenant du schisandrae fructus pour prévenir ou traiter une maladie liée à la circulation sanguine
WO2009104900A2 (fr) Composition comprenant un extrait de la fleur de lonicera japonica thunb pour le traitement et la prévention d'affections arthritiques
KR102663306B1 (ko) 치주질환 예방, 개선 또는 치료용 조성물
WO2012105816A2 (fr) Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci
WO2011019153A2 (fr) Composition pour la prévention ou le traitement de l’arthrite, contenant un extrait d’un mélange médicinal à base de plantes de schisandra chinensis baillon, scutellaria baicalensis et kalopanax pictus nakai en tant qu’ingrédient actif
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
Johnson et al. Dalbergia sissoo Roxb. ex-DC.-A Monograph.
WO2022154448A1 (fr) Composition comprenant un extrait composite naturel en guise de principe actif pour moduler ou renforcer l'immunité
WO2018008999A1 (fr) Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète
KR101671057B1 (ko) 여정자 추출물 및 지골피 추출물을 유효성분으로 함유하는 치주질환의 예방 또는 치료용 경구투여 조성물
WO2023282624A1 (fr) Composition pour prévenir atténuer l'obésité comprenant un extrait d'anchois ou un acide néochlorogénique en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16780300

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16780300

Country of ref document: EP

Kind code of ref document: A1